<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04862559</url>
  </required_header>
  <id_info>
    <org_study_id>NT-CLP-02</org_study_id>
    <nct_id>NCT04862559</nct_id>
  </id_info>
  <brief_title>A Single Center Study to Evaluate the Safety of the NovaCross Microcatheter in Crossing Chronic Total Occlusions</brief_title>
  <official_title>A Prospective, Single Center, Non-randomized, Single Arm, Open Label, Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nitiloop Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nitiloop Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, single-center, prospective, pivotal study in which the investigational&#xD;
      device, NovaCross™ micro-catheter, will be tested in up to 15 patients scheduled to undergo&#xD;
      CTO-PCI using an anterograde approach.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Actual">September 17, 2017</completion_date>
  <primary_completion_date type="Actual">September 17, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular Adverse Events (Primary Safety)</measure>
    <time_frame>30 days</time_frame>
    <description>Accumulative incidence of Major Adverse Cardiovascular Events (MACE), defined as the composite of death, myocardial infarction (MI), or urgent revascularization (target vessel revascularization (TVR) or urgent coronary artery bypass surgery (CABG)).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Technical Success (Primary Efficacy)</measure>
    <time_frame>1 day</time_frame>
    <description>Intra-procedural technical success, defined as the ability of the NovaCross™ microcatheter to successfully facilitate placement of a guidewire beyond a native coronary chronic total occlusion in the true vessel lumen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>1 day</time_frame>
    <description>The ability to cross the lesion with a guidewire in the true lumen, effectively dilate the CTO lesion, and place a coronary stent with residual lumen stenosis of less than 30% while restoring antegrade TIMI 3 flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assistance in Guidewire Penetration</measure>
    <time_frame>1 day</time_frame>
    <description>The ability of the NovaCross™ micro-catheter to facilitate a guidewire successfully penetrating the proximal cap of the CTO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crossability</measure>
    <time_frame>1 day</time_frame>
    <description>The effectiveness of the extendable portion in intra-CTO microcatheter crossability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedual Visualization</measure>
    <time_frame>1 day</time_frame>
    <description>The ability to have full visualization of the NovaCross during the CTO procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operator Ease of Use</measure>
    <time_frame>1 day</time_frame>
    <description>Assess the usability of the NovaCross™ by the operator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Related Perforation Rate</measure>
    <time_frame>1 day</time_frame>
    <description>Device-related perforation at the site of target coronary lesion and/or its proximal reference segment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Chronic Total Occlusion</condition>
  <arm_group>
    <arm_group_label>NovaCross</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm are treated with the investigational device, NovaCross micro-cetheter, to facilitate the opening of a chronic total occlusion (CTO)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NovaCross</intervention_name>
    <description>A device that is intended to asisst interventional cardiologists during catheterization to cross and open coronary chronic total occlusions</description>
    <arm_group_label>NovaCross</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult aged 25-80&#xD;
&#xD;
          -  Patient understands and has signed the study informed consent form.&#xD;
&#xD;
          -  Patient is a suitable candidate for non-emergent, coronary angioplasty&#xD;
&#xD;
          -  Patient has an angiographic documented Chronic Total Occlusion (i.e. &gt;3 months&#xD;
             occlusion duration either by documentation or PI assessment Investigator) showing&#xD;
             distal TIMI flow 0.&#xD;
&#xD;
          -  Coronary angiography of CTO lesion reveals satisfactory distal vessel visualization&#xD;
&#xD;
          -  CTO lesion is located in a coronary vessel with a reference diameter of at least 2&#xD;
             millimeters.&#xD;
&#xD;
          -  CTO lesion is suitable for antegrade approach.&#xD;
&#xD;
          -  Left ventricle ejection fraction &gt; 25%&#xD;
&#xD;
          -  Body Mass Index (BMI) &lt; 40&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient unable to give informed consent.&#xD;
&#xD;
          -  Patient is participating in another study with any investigational drug or device.&#xD;
&#xD;
          -  Patient is known or suspected not to tolerate the contrast agent.&#xD;
&#xD;
          -  Aorto-ostial CTO location (Ostial bifurcation origins may be considered), SVG CTO.&#xD;
&#xD;
          -  Intolerance to Aspirin and/or inability to tolerate a second antiplatelet agent&#xD;
             (Clopidogrel and Prasugrel and Ticagrelor).&#xD;
&#xD;
          -  Appearance of a fresh thrombus or intraluminal filling defects.&#xD;
&#xD;
          -  Recent major cerebrovascular event (stroke or TIA within 30 days)&#xD;
&#xD;
          -  Significant anemia (hemoglobin &lt; 8.0 mg / dl)&#xD;
&#xD;
          -  Unstable angina requiring emergent percutaneous trans-luminal coronary angioplasty&#xD;
             (PTCA) or coronary artery bypass graft (CABG)&#xD;
&#xD;
          -  Recent myocardial infarction (MI) (within the past two weeks)&#xD;
&#xD;
          -  Unwillingness or inability to comply with any protocol requirements&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chanan Schneider, Mr.</last_name>
    <role>Study Director</role>
    <affiliation>Company Employee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>April 23, 2021</study_first_submitted>
  <study_first_submitted_qc>April 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

